# Regeneron Pharmaceuticals Revenue

NASDAQ: REGN · Reporting currency: USD

[Interactive page](https://beanvest.com/stock/regn/revenue) · [JSON with these options](https://beanvest.com/stock/regn/revenue.json?range=5Y&deductSbc=false&limit=200&offset=0&frequency=quarterly&wacc=7.9) · [Raw filing inputs](https://beanvest.com/api/v2/financials/regn)

Frequency: quarterly. Newest first. Retrieved: 2026-10-23T15:38:11.499Z.
Coverage: 2010-06-30 to 2026-06-30. Rows 1–65 of 65.
Snapshot checked: 2026-10-19T21:59:30.430Z. Last validated: 2026-10-24T14:58:13.916Z.

## Definitions

- **Total revenue** (`total_revenue`, USD_millions): Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.

## Values

| Period | End date | Total revenue (USD_millions) |
| --- | --- | --- |
| 2026-Q2 | 2026-06-30 | 4290.7 |
| 2026-Q1 | 2026-03-31 | 3605.4 |
| 2025-Q4 | 2025-12-31 | 3884.3 |
| 2025-Q3 | 2025-09-30 | 3754.3 |
| 2025-Q2 | 2025-06-30 | 3675.6 |
| 2025-Q1 | 2025-03-31 | 3028.7 |
| 2024-Q4 | 2024-12-31 | 3789.2 |
| 2024-Q3 | 2024-09-30 | 3720.7 |
| 2024-Q2 | 2024-06-30 | 3547.1 |
| 2024-Q1 | 2024-03-31 | 3145 |
| 2023-Q4 | 2023-12-31 | 3434.3 |
| 2023-Q3 | 2023-09-30 | 3362.7 |
| 2023-Q2 | 2023-06-30 | 3158.1 |
| 2023-Q1 | 2023-03-31 | 3162.1 |
| 2022-Q4 | 2022-12-31 | 3414.4 |
| 2022-Q3 | 2022-09-30 | 2936.2 |
| 2022-Q2 | 2022-06-30 | 2857.2 |
| 2022-Q1 | 2022-03-31 | 2965.1 |
| 2021-Q4 | 2021-12-31 | 4951.7 |
| 2021-Q3 | 2021-09-30 | 3452.8 |
| 2021-Q2 | 2021-06-30 | 5138.5 |
| 2021-Q1 | 2021-03-31 | 2528.7 |
| 2020-Q4 | 2020-12-31 | 2422.9 |
| 2020-Q3 | 2020-09-30 | 2294 |
| 2020-Q2 | 2020-06-30 | 1952 |
| 2020-Q1 | 2020-03-31 | 1828.2 |
| 2019-Q4 | 2019-12-31 | 2169.5 |
| 2019-Q3 | 2019-09-30 | 2048.4 |
| 2019-Q2 | 2019-06-30 | 1933.7 |
| 2019-Q1 | 2019-03-31 | 1711.8 |
| 2018-Q4 | 2018-12-31 | 1927.8 |
| 2018-Q3 | 2018-09-30 | 1663.496 |
| 2018-Q2 | 2018-06-30 | 1608.022 |
| 2018-Q1 | 2018-03-31 | 1511.485 |
| 2017-Q4 | 2017-12-31 | 1582.447 |
| 2017-Q3 | 2017-09-30 | 1500.673 |
| 2017-Q2 | 2017-06-30 | 1470.116 |
| 2017-Q1 | 2017-03-31 | 1318.991 |
| 2016-Q4 | 2016-12-31 | 1226.827 |
| 2016-Q3 | 2016-09-30 | 1220.122 |
| 2016-Q2 | 2016-06-30 | 1212.629 |
| 2016-Q1 | 2016-03-31 | 1200.849 |
| 2015-Q4 | 2015-12-31 | 1098.077 |
| 2015-Q3 | 2015-09-30 | 1137.422 |
| 2015-Q2 | 2015-06-30 | 998.617 |
| 2015-Q1 | 2015-03-31 | 869.612 |
| 2014-Q4 | 2014-12-31 | 802.329 |
| 2014-Q3 | 2014-09-30 | 725.788 |
| 2014-Q2 | 2014-06-30 | 665.7 |
| 2014-Q1 | 2014-03-31 | 625.74 |
| 2013-Q4 | 2013-12-31 | 610.412 |
| 2013-Q3 | 2013-09-30 | 597.027 |
| 2013-Q2 | 2013-06-30 | 457.642 |
| 2013-Q1 | 2013-03-31 | 439.664 |
| 2012-Q4 | 2012-12-31 | 414.602 |
| 2012-Q3 | 2012-09-30 | 427.687 |
| 2012-Q2 | 2012-06-30 | 304.399 |
| 2012-Q1 | 2012-03-31 | 231.789 |
| 2011-Q4 | 2011-12-31 | 122.977 |
| 2011-Q3 | 2011-09-30 | 102.833 |
| 2011-Q2 | 2011-06-30 | 107.81 |
| 2011-Q1 | 2011-03-31 | 112.204 |
| 2010-Q4 | 2010-12-31 | 133.675 |
| 2010-Q3 | 2010-09-30 | 105.979 |
| 2010-Q2 | 2010-06-30 | 115.886 |

## Sources

- [sec-0000872589-8ac8537cd8b5](https://data.sec.gov/api/xbrl/companyfacts/CIK0000872589.json) · Retrieved 2026-09-28T07:37:41.538Z · SHA-256 8ac8537cd8b5e571e7f527aae3e223c6a7cdab1260fd8035e278ac184b4901b4
- [inline-0000872589-e015dcab4468](https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm) · Retrieved 2026-10-21T06:17:09.363Z · SHA-256 e015dcab4468b8135f245f1d6f2fa32d6411f097396be0017fe84fe60a97d9ed
- [inline-0000872589-a6f2d3c9c545](https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm) · Retrieved 2026-10-21T06:17:09.363Z · SHA-256 a6f2d3c9c54515ce84b819d980979f3180312e3574ea2862209555137aa358ee
- [inline-0000872589-fef32e68a903](https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm) · Retrieved 2026-10-21T06:17:09.363Z · SHA-256 fef32e68a90387fad915fa052daada10360908f3ff6e0c015b083809e4b51005

## Data conventions

- Null means an unavailable input or undefined calculation, never zero. Values are unrounded; money and shares are in millions unless a column states otherwise.
- Fiscal periods use actual reporting start/end dates. Annual reported values are not constructed by adding quarterly EPS or weighted share counts. Partial years are labelled.
- FCF uses operating cash flow minus reported cash capital investment, preferring PPE purchases. The productive-assets fallback can also include software and intangibles. Acquisitions and noncash leases are excluded. Deduct SBC is an optional economic-cost scenario; missing SBC remains unavailable.
- SBC / FCF and SBC / OCF compare amounts from the same fiscal period. SBC / FCF always uses FCF before SBC deduction; nonpositive denominators are undefined and values above 100% remain valid.
- Capital allocation percentages describe available tracked cash uses, not all company spending or a fraction of OCF. Missing categories remain null, negative payments are excluded and SBC is noncash. Annual shares use reported annual amounts.
- Valuation uses completed, split-adjusted closes without dividend adjustment and a complete trailing year. Financial bases become eligible after publication; selected facts can contain later restatements. This is not a vintage-filings backtest.
- Mean and median use all valid observations in the selected date range before pagination. Historical pricing labels compare the latest positive value with its own median and do not estimate intrinsic fair value.
- Reporting currencies are retained without conversion. USD market capitalization, where available, is a separate dated Nasdaq snapshot.
- WACC is an editable US industry scenario across history, not a historical company cost of capital. Industry exclusions, missing inputs and pending filings remain explicit.